Last €4.06 EUR
Change Today +0.232 / 6.06%
Volume 0.0
F6T On Other Exchanges
As of 9:37 AM 12/23/14 All times are local (Market data is delayed by at least 15 minutes).

fate therapeutics inc (F6T) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/27/14 - €8.88
52 Week Low
12/16/14 - €2.78
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for FATE THERAPEUTICS INC (F6T)

Related News

No related news articles were found.

fate therapeutics inc (F6T) Related Businessweek News

No Related Businessweek News Found

fate therapeutics inc (F6T) Details

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops pharmacologic modulators of adult stem cells to treat orphan diseases. Its hematopoietic stem cell (HSC) modulation platform focuses on the ex vivo pharmacologic optimization of hematopoietic stem cells, which are adult stem cells that regenerate various types of blood cells throughout a person’s lifespan; and satellite cell modulation platform focuses on the in vivo pharmacologic activation of satellite stem cells that are adult stem cells that regenerate muscle throughout a person’s lifespan. The company’s lead product candidate includes ProHema, a pharmacologically-modulated HSC therapeutic derived from umbilical cord blood that is in Phase II clinical development for hematologic malignancies. It is developing pharmacologically optimized HSC therapeutics for the treatment of lysosomal storage disorders within the central nervous system; and Wnt7a Analogs that is in preclinical studies for regeneration in muscular dystrophies. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.

37 Employees
Last Reported Date: 03/17/14
Founded in 2007

fate therapeutics inc (F6T) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $350.0K
Chief Financial Officer, Chief Operating Offi...
Total Annual Compensation: $256.0K
Chief Medical Officer
Total Annual Compensation: $318.0K
Compensation as of Fiscal Year 2013.

fate therapeutics inc (F6T) Key Developments

Fate Therapeutics, Inc. Announces Interim Data from Ongoing Phase 2 Puma Study

Fate Therapeutics, Inc. reported initial data from the first 12 subjects administered PROHEMA® in the Company's ongoing Phase 2 PUMA study and announced that the study's independent Data Monitoring Committee (iDMC) supported continuation of the clinical trial following a second planned interim safety review. These early data showed that subjects administered PROHEMA, the Company's lead ex vivo programmed hematopoietic cellular therapeutic derived from umbilical cord blood, had an improved median time of neutrophil engraftment and an increased incidence of early neutrophil engraftment. PROHEMA is derived by programming the biological properties of allogeneic hematopoietic cells ex vivo using a small molecule harmacologic modulator, optimizing their in vivo therapeutic potential. Of the first 12 subjects administered PROHEMA in the Phase 2 PUMA study, 10 subjects received myeloablative conditioning (MAC) and two subjects received reduced-intensity conditioning (RIC). Eight of 10 PROHEMA subjects receiving MAC achieved neutrophil engraftment, with a median time of engraftment of 20 days. One of two PROHEMA subjects receiving RIC achieved neutrophil engraftment, which was reached on Day 14. Historical median times of neutrophil engraftment are approximately 26 days for patients receiving MAC and 21 days for patients receiving RIC based on multi-center reports published in the literature of adult patients undergoing double umbilical cord blood transplantation in the United States. Six of the nine engrafting subjects administered PROHEMA in the PUMA study achieved neutrophil engraftment prior to these historical median times.

Fate Therapeutics, Inc. Unveils Preclinical Findings of Newly-Identified Small Molecule Modulator Combination for Ex Vivo Programming of Mobilized Peripheral Blood

Fate Therapeutics, Inc. released preclinical data highlighting the pharmacological properties of ex vivo programmed hematopoietic cells sourced from mobilized peripheral blood at the 56(th) Annual Meeting and Exposition of the American Society of Hematology (ASH). Using a newly-identified combination of two small molecule modulators, scientists from Fate Therapeutics demonstrated that both T-cells and CD34+ cells from mobilized peripheral blood can be modulated ex vivo, with preclinical evidence pointing to the programmed hematopoietic cells having improved therapeutic potential. Gene expression analysis of CD34+ cells sourced from mobilized peripheral blood co-modulated with FT1050 and FT4145 showed a 60-fold increase in the expression of the key homing receptor CXCR4, and ex vivo programmed CD34+ cells demonstrated a statistically significant increase in engraftment in preclinical models as compared to unmodulated cells. Additionally, genome-wide expression analysis of the T-cell compartment of mobilized peripheral blood, including CD8+, CD4+ and regulatory T-cells, revealed the induction of genes involved in cell cycle (e.g., CCND1, CCNE1), immune tolerance (e.g., DUSP5, FLT1) and anti-viral properties (e.g., CD55, EFNB2). Additionally, following a five-day culture in the presence of activating beads, T-cells co-modulated with FT1050 and FT4145 were found to have reduced proliferation rates and decreased cell-surface protein expression of ICOS, a key T-cell activation marker, relative to unmodulated cells. Collectively, these preclinical findings point to the therapeutic potential for ex vivo programmed hematopoietic cells to mitigate T-cell mediated complications and improve outcomes in patients undergoing hematopoietic stem cell transplant with mobilized peripheral blood as a cell source. Mobilized peripheral blood is the predominant cell source used in hematopoietic stem cell (HSC) transplantation.

Fate Therapeutics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 12:10 PM

Fate Therapeutics, Inc. Presents at 26th Annual Piper Jaffray Healthcare Conference, Dec-02-2014 12:10 PM. Venue: The New York Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Christian Weyer, Chief Executive Officer, President and Director.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
F6T:GR €4.06 EUR +0.232

F6T Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for F6T.
View Industry Companies

Industry Analysis


Industry Average

Valuation F6T Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 3.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FATE THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at